🏛️ Verified NIH Record • Updated 2026-08-19
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations (NCT07109726)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Terremoto Biosciences Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- City of Hope — Duarte, California
- City of Hope, Irvine — Irvine, California
- Florida Cancer Specialists - Lake Nona — Orlando, Florida
- City of Hope, Chicago — Zion, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Mayo Rochester — Rochester, Minnesota
- Washington Univ. School of Medicine — St Louis, Missouri
- Nebraska Cancer Specialists — Omaha, Nebraska
- Carolina BioOncology Institute — Huntersville, North Carolina
- UH Cleveland Medical Center — Cleveland, Ohio
- Sarah Cannon Nashville — Nashville, Tennessee
- NEXT Oncology — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- START Center for Cancer Research — San Antonio, Texas
- START Center for Cancer Research — West Valley City, Utah
- NEXT Oncology — Fairfax, Virginia
- Froedtert & MCW Cancer Center — Milwaukee, Wisconsin
- PanOncology Trials — San Juan,
📞 Contact the Study Coordinator
Phone: (888) 682-1551
Email: clinicaltrials@terremotobio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.